secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2026-08-05T20:10:16+00:00
Accession:  0001193125-26-335101
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enliven Therapeutics Q2 net loss $32.5M; positive Phase 1 data for ELVN-001 in CML; cash $895M into 2030
--------------------------------------------------------------------------------

- Net loss of $32.5M for Q2 2026 vs $25.3M in Q2 2025; R&D expenses $29.0M.
- Cash, cash equivalents and marketable securities of $895.2M as of June 30, 2026, expected to fund operations into 2030.
- ELVN-001 Phase 1 data: 61% overall MMR, 48% MMR by 24 weeks in 80mg QD cohort; favorable safety profile.
- FDA alignment on Phase 3 ENABLE-2 trial design; 80mg QD selected as recommended dose; Fast Track Designation granted.
- Expect to initiate ENABLE-2 Phase 3 trial in H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312526335101/0001193125-26-335101-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312526335101/elvn-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-335101

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer